Idebenone
Idebenon · Avan · debenone · Idebenone powder · 6-(10- · Daruma · Mnesis · QSA-10
Identifikatoren & physikalische Daten
| CAS No. | 58186-27-9 |
|---|---|
| Summenformel | C19H30O5 |
| Durchschnittliche Molmasse | 338,4 g/mol |
| Monoisotopische Masse | 338,20932405 g/mol |
| SMILES | COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O |
| InChIKey | JGPMMRGNQUBGND-UHFFFAOYSA-N |
| PubChem CID | 3686 |
| ChEMBL | CHEMBL252556 |
| ChEBI | CHEBI:31687 |
| EC No. | 814-253-7 |
| DTXSID | DTXSID0040678 |
Chemische & physikalische Eigenschaften
| XLogP | 4,3 |
|---|---|
| Polarare Oberfläche (TPSA) | 72,8 |
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 5 |
| Frei drehbare Bindungen | 12 |
| Schwere Atome | 24 |
| Formalladung | 0 |
| Komplexität | 502 |
| Collision Cross Section | 173.7 Ų [M+H-H2O]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]181.56 Ų [M+Na]+ [CCS Type: TW181.21 Ų [M+K]+ [CCS Type: TW175.92 Ų [M+H]+ [CCS Type: TW178.6 Ų [M+H]+ [CCS Type: TW |
| Schmelzpunkt | 52-550C |
| Siedepunkt | 497.3±45.0 °C(Predicted) |
| Dichte | 1.08±0.1 g/cm3(Predicted) |
| Lagerbedingungen | room temp |
| Löslichkeit | Soluble in DMSO (up to 25 mg/ml). |
| pKa (Säurekonstante) | 15.20±0.10(Predicted) |
| Aggregatzustand | Solid |
| Farbe | Orange |
| Merck | 14,4888 |
| Stabilität | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| Kosmetik-Inhaltsstoffe Funktionen | ANTIOXIDANT |
| InChI | InChI=1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3 |
| InChIKey | JGPMMRGNQUBGND-UHFFFAOYSA-N |
| SMILES | C1(=O)C(OC)=C(OC)C(=O)C(C)=C1CCCCCCCCCCO |
| LogP (Verteilungskoeffizient) | 3.490 (est) |
| CAS Datenbank | 58186-27-9(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 25% (1 of 4) of reports.DangerH228 (25%): Flammable solid [Danger Flammable solids]H302 (25%): Harmful if swallowed [Warning Acute toxicity, oral]H315 (25%): Causes skin irritation [Warning Skin corrosion/irritation]H319 (25%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]H335 (25%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposureRespiratory tract irritation]P210, P240, P241, P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P370+P378, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 4 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Reported as not meeting GHS hazard criteria per 1 of 4 reports by companies.There are 3 notifications provided by 3 of 4 reports by companies with hazard statement code(s).Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| Hazard Classes and Categories | Flam. Sol. 2 (25%)Acute Tox. 4 (25%)Skin Irrit. 2 (25%)Eye Irrit. 2A (25%)STOT SE 3 (25%) |
| Toxizitätsübersicht | Safe in the present practices of use and concentration. Ingredient, concentration, and use information are available in documents discoverable at https://cir-reports.cir-safety.org |
| Wassergefährdungsklasse (WGK) | 3 |
| Zollcode | 2933399990 |
| RTECS-Nr. | GU5290000 |
| Gefahrensymbole | Xi |
Anwendungen & Verwendung
Beschreibung
Idebenone is an organic compound belonging to the quinone family, being similar to coenzyme Q-10. It is a kind of drug developed by Takeda Pharmaceutical Company for the treatment of Alzheimer’s disease and some other cognitive defects. However, these have been not very much progress associated with this indication. It is now also used for the treatment of Friedreich’s ataxia with a positive effect on cardiac hypertrophy and neurological function. However, this indication is only approved in Canada, not in Europe and US. It is now under investigation on its efficacy for the treatment of Duchenne muscular dystrophy, Leber’s hereditary optic neuropathy, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) as well as primary progressive multiple sclerosis. The efficacy of this drug still demands more evidences.
Verwenden
idebenone is an anti-oxidant capable of protecting the skin from a variety of free-radical attacks, including the formation of secondary chemicals that negatively affect skin physiology. It is said to improve intrinsic as well as extrinsic skin damage caused by freeradical formation. Idebenone is a synthetically manufactured form of coenzyme Q10 and has a smaller molecular structure. This allows it to penetrate the skin and apparently the cellular membrane. Clinical studies demonstrate a visible improvement in photodamaged skin, reduced skin roughness and dryness, decreased fine lines and wrinkles, and increased skin hydration. In addition, idebenone helps improve hyperpigmentation because its molecular structure is similar to that of hydroquinone. Although most of the associated benefits are seen primarily in the epidermis, some increase in dermal collagen has also been confirmed. Idebenone has been used for such health-related problems as Alzheimer’s and heart disease.